Sitagliptin - Enhancing incretin action

Ian W. Campbell, Caroline Day*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.

Original languageEnglish
Pages (from-to)134-139
Number of pages6
JournalBritish Journal of Diabetes and Vascular Disease
Issue number3
Publication statusPublished - 1 May 2007


  • DPP-4
  • Gliptin
  • Incretin
  • Inhibitor
  • Sitagliptin
  • Type 2 diabetes


Dive into the research topics of 'Sitagliptin - Enhancing incretin action'. Together they form a unique fingerprint.

Cite this